FDA Announces Approval of Evkeeza for Homozygous Familial Hypercholesterolemia in Children

Published Date: 26 Mar 2023

Evkeeza is the first angiopoietin-like 3 (ANGPTL3) inhibitor used in patients under 5 years of age to control elevated HoFH low-density lipoprotein cholesterol (LDL-C) levels.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Does pollution cause cancer?

2.

AI is equally capable of reading breast cancer scans as human radiologists.

3.

EVP Beats Cisplatin for Resectable MIBC

4.

New research points out a promising strategy for treating metastatic medulloblastoma

5.

Academics + Pharma = Big Bucks; New CAR-T Warnings; Patients Seek Cancer Tests.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot